The Supreme Court’s dismissal of Novartis’s application seeking patent protection for its anti-cancer drug is most welcome. No company should be allowed to exploit patients by selling patented, expensive drugs — which have not been the result of ‘inventions’ per se — used in the treatment of serious diseases and conditions. The right to manufacture generic versions of such drugs should be given to domestic companies.
K.A. Solaman,
The Telegraph, Kolkata. April 10, 2013
No comments:
Post a Comment